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Risk factors for disease states are rigorously defined. This
analysis considers the definition of a risk factor as applied
to the question of whether the serum phosphorus level is
a risk factor for cardiovascular disease. Observational
studies strongly suggest that phosphorus is associated
with cardiovascular risk, and definitive prospective animal
studies are supportive. A plausible mechanism of action
has been discovered demonstrating that phosphorus
stimulates osteoblastic transition of cells in the neointima
of atherosclerotic plaques, which, if prevented, blocks
vascular calcification. However, prospective studies
demonstrating that modulation of the putative risk factor
affects clinical outcomes are lacking, and phosphorus,
as yet, does not qualify as a cardiovascular risk factor.
This is a clarion call for additional research.
Kidney International (2011) 79 (Suppl 121), S9–S13; doi:10.1038/ki.2011.24;
published online 23 February 2011
KEYWORDS: arterial calcification; cardiovascular disease; mortality;
phosphate
TO CITE THIS ARTICLE:
Hruska K, Mathew S, Lund R, Fang Y and Sugatani T. Cardiovascular risk
factors in chronic kidney disease: does phosphate qualify? Kidney Int 2011;
79 (Suppl 121): S9–S13.
Among the 25 million American patients with stage 2–5
chronic kidney disease (CKD), cardiovascular disease causes
a disproportionately high mortality risk. Patients with CKD
are more likely to die (often of cardiovascular causes) than to
progress to dialysis.
1 The risk of death is especially high in
late-stage kidney disease; a 30-year-old patient with end-stage
renal disease faces an equivalent risk of death to a 90-year-old
without CKD.
2 The cardiovascular risk factors generally
considered do not explain the heightened cardiovascular risk
in CKD.
3 Vascular calciﬁcation
4,5 and hyperphosphatemia
6
drive cardiovascular risk in CKD, and they are related.
Risk factors are rigorously deﬁned by four types of
evidence: (1) observational studies; (2) deﬁnitive prospective
translational or clinical studies; (3) mechanism of action
studies; and (4) outcome studies showing risk reduction
when the putative factor is corrected. Serum phosphorus, at
the current state of our knowledge, is associated with the ﬁrst
three of these four lines of evidence. One early observational
outcome study has also shown risk reduction beneﬁts with
correction of phosphate levels in patients with CKD. This
review will summarize current evidence for phosphate as
a cardiovascular risk factor in the general population and
among patients with CKD.
OBSERVATIONAL STUDIES OF PHOSPHATE AND
CARDIOVASCULAR RISK
Serum phosphorus and mortality risk have been analyzed in
multiple observational studies. In patients with end-stage
renal disease on dialysis (40,538 hemodialysis patients), those
with serum phosphorus 46.0 to 7.0mg/dl had a relative risk
of death 1.25 times that of those with serum phosphorus
p5mg/dl. The lowest serum phosphate category (o3mg/dl)
showed slightly increased risk (1.2 versus 4.5mg/dl).
7 In a
retrospective cohort study of 6730 US veterans with CKD not
receiving dialysis (those transplanted or without phosphorus
measurements were excluded), the adjusted hazard ratio for
death rose to 1.90 in patients with serum phosphorus
45.0mg/dl (compared with patients with serum phosphorus
o2.5mg/dl).
8
In the general population, serum phosphorus has been
associated with the risk of cardiovascular disease (Figure 1).
The Framingham Offspring Study,
9 deleted of participants
with histories of CKD, revealed that increasing serum
phosphorus was associated with a continuous increasing
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peripheral vascular disease, or heart failure). In a post hoc
analysis of the Cholesterol and Recurrent Events study
10
(Figure 1), serum phosphate showed a graded independent
relationship to risk of death and new cardiovascular events
in patients who had suffered heart attacks previously and
had normal kidney function. In both the Cholesterol
and Recurrent Events study and the US Third Health and
Nutrition Examination Survey populations, elevation of
serum alkaline phosphatase and serum phosphate together
conferred greater risk than either parameter alone.
11
How might serum phosphorus affect atherosclerosis? In
CKD, we associate hyperphosphatemia causally with vascular
calciﬁcation, which stiffens arteries and leads to cardio-
vascular events. In young and middle-aged adults without
CKD, serum phosphorus levels were associated with vascular
stiffness and coronary artery calcium levels in the Multi-
Ethnic Study of Atherosclerosis. In middle-aged participants
with mild-to-moderate CKD,
12 the ankle–brachial index
increased in parallel with serum phosphorus levels within
the normal range. In the Coronary Artery Risk Development
in Young Adults study, which was a 15-year prospective
observational study,
13 10% of the participants with 15-year
data experienced signiﬁcant coronary calciﬁcation during
follow-up, related to the serum phosphorus level at the
beginning of the follow-up period.
DEFINITIVE PROSPECTIVE TRANSLATIONAL OR CLINICAL
STUDIES: HOW DOES PHOSPHORUS FUNCTION AS A RISK
FACTOR FOR CARDIOVASCULAR MORTALITY?
The complexity of human disease causing cardiovascular risk
requires a translational model to dissect the role of phos-
phorus in vascular calciﬁcation and coronary artery disease
development in CKD. There are two types of translational
studies that address the issue of phosphorus as a cardio-
vascular risk. In the ﬁrst, genetic engineering was used to
produce deﬁciency of the ﬁbroblast growth factor-23 skeletal
hormone, which is responsible for regulating renal phosphate
excretion. Mice with ﬁbroblast growth factor-23 deﬁciency
develop hyperphosphatemia, excess calcitriol and vascular
calciﬁcation, and have shortened life spans. Feeding these
mice low-phosphate diets corrects hyperphosphatemia,
eliminates vascular calciﬁcation, and lengthens their life
span.
The second type of study that demonstrates the function
of inorganic phosphate as a cardiovascular risk factor
comprises studies in animal models of atherosclerosis in
which hyperphosphatemia is induced by CKD. We have used
the low-density lipoprotein receptor-deﬁcient mouse (ldlr
–/–)
fed a high-fat diet with ablative CKD. LDL
–/– mice fed
high-fat diets develop hypercholesterolemia, metabolic syn-
drome, and vascular calciﬁcation. CKD added to this model
induces hyperphosphatemia (beginning at stage 3 CKD) and
increases vascular, especially aortic, calciﬁcation.
14 Adminis-
tration of phosphate binders and bone morphogenetic
protein (BMP)-7 in this model prevented hyperphosphate-
mia by reducing phosphate absorption and sending serum
phosphate into the skeleton.
15,16 In mice with established
vascular calciﬁcation (atherogenic diet begun at 10 weeks,
CKD induced by 14 weeks, and phosphate binder or BMP-7
administered from 22 to 28 weeks), control of phosphate for
weeks 22–28 with sevelamer carbonate or BMP-7 diminished
vascular calciﬁcation and prevented cardiac hypertrophy.
15,16
The study with BMP-7 originally addressed concerns that
BMP-7 might stimulate vascular calciﬁcation, but in fact
showed BMP-7 to be therapeutic, decreasing aortic calciﬁca-
tion below control levels and stimulating bone formation.
The stimulation of bone formation was the mechanism of
BMP-7-induced correction of hyperphosphatemia, and a
component of the action against vascular calciﬁcation.
MECHANISM OF ACTION STUDIES
A scientiﬁc consensus more advanced than mere plausibility
has developed with regard to the mechanism by which
high serum phosphate leads to vascular calciﬁcation and
cardiovascular risk. Pathologically, there are two types of
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Figure 1|Observational studies from the general population, which suggest that phosphorus is a cardiovascular risk factor. The left
panel assembles data from Dhingra et al.
9 Cardiovascular disease (CVD) was scored as fatal/non-fatal MI, angina, cerebrovascular events,
peripheral vascular disease, or heart failure. Hazard ratios are adjusted for age, sex, body mass index, diabetes, blood pressure, treatment of
hypertension, smoking, alcohol consumption, total cholesterol/high-density cholesterol ratio, hemoglobin, serum albumin, estimated
glomerular filtration rate, proteinuria, and high-sensitivity C-reactive protein. The right panel is adapted with permission from Tonelli et al.
10
Hazard ratio values are adjusted for baseline age, sex, race, smoking status, diabetes, waist-to-hip circumference, fasting glucose, glomerular
filtration rate, hemoglobin, serum albumin, aspirin use, and left ventricular ejection fraction. N¼4127. CKD, chronic kidney disease; MI,
myocardial infarction.
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of the smooth muscle tunica media and atherosclerotic
calciﬁcation of smooth muscle cells in plaque neointima
(Figure 2). Atherosclerotic calciﬁcation is more important in
cardiovascular mortality risk, and tunica media calciﬁcation
is more important in vascular stiffness.
17 In atherosclerotic
calciﬁcation, neointimal cells express an osteoblastic pheno-
type, either by migration and differentiation of pericytes
or by dedifferentiation, migration, and redifferentiation of
smooth muscle cells. Initial renal injury induces dedifferen-
tiation of vascular smooth muscle cells, which makes them
migratory and vulnerable to osteoblastic induction by
BMP-2. Additional studies have shown phosphorus to be a
molecule capable of stimulating signal transduction.
18,19 We
have shown inorganic phosphate to stimulate expression
of osterix both in vivo in our ldlr
–/– high-fat fed CKD mice
and in vitro in human aortic smooth muscle cells derived
from atherosclerotic donors with early CKD
20 (Figure 3).
Osterix is an osteoblast transcription factor required for
cellular stimulation of matrix mineralization.
21 Primary
mouse or human smooth muscle cells in vitro transitioned
from normal to high-phosphate culture medium (1 to
2mmol/l) will mineralize their extracellular matrix in
2–3 weeks.
20 Blocking of osterix expression in the presence
of high phosphorus prevents mineralization.
Reducing serum phosphorus (for example, with phos-
phate binders) reverses osteoblastic differentiation of
vascular cells and reverses vascular calciﬁcation.
20 Osteo-
blastic transition and calciﬁcation of smooth muscle cells
(akin to bone formation) in the atherosclerotic plaque is an
active and reversible process. Osteoclasts and large multi-
nucleated macrophages are present in plaques and can
actually reabsorb calciﬁcation when serum phosphorus is
decreased.
EFFECTS OF CKD ON PHOSPHATE HOMEOSTASIS
The phosphate balance diagram is shown in Figure 4. In
health, bone formation and resorption balance each other,
and there is capacity in the skeletal mineralization fronts to
absorb a transient positive phosphate balance, which would
be converted into bone. This permits the skeleton to function
physiologically as a phosphate and calcium reservoir. In
CKD-related mineral and bone disorder, renal osteodystro-
phy causes excess bone resorption over bone formation in
both high- and low-turnover forms of osteodystrophy. This
blocks the normal reservoir function of the skeleton. In CKD,
increasing fractional excretion of phosphorus (via adaptation
of intact nephrons) maintains phosphorus balance in the
early stages, but eventually reduction in the tubular reabsorp-
tion of phosphate cannot keep pace and phosphate balance
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Figure 3|Hyperphosphatemia stimulates expression of
osterix in the aortas of low-density lipoprotein receptor-
deficient mouse (ldlr
–/–) with chronic kidney disease (CKD)
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Figure 4|The phosphate balance diagram in chronic kidney
disease (CKD) showing positive balance and a skeletal
contribution to hyperphosphatemia, which blocks skeletal
reservoir function. Reproduced with permission from Mathew
et al.
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Vascular calcification (VC) in CKD
In CKD both forms of VC are observed in the large arteries,
calciphylaxis is mainly Mönkeberg, coronary artery calcification
and cardiac valve calcification are atherosclerotic
Atherosclerotic
Arterial intimal calcification
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Figure 2|The two major types of large artery calcification
stimulated by chronic kidney disease (CKD) are atherosclerotic
neointimal calcification and medial calcification. Reproduced
with permission from Dr Gerard London.
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phatemia occurs. The increased bone resorption contributes
to the exchangeable phosphate pool, and to hyperphos-
phatemia. When extra phosphorus is present from a positive
balance, in this situation it exits from the exchangeable pool
into heterotopic deposition sites. Therefore, the skeleton
contributes to heterotopic calciﬁcation especially in the
vasculature in CKD.
The pathophysiology of phosphorus balance in CKD is
dependent on a recently discovered skeletal hormone,
ﬁbroblast growth factor-23, and its relevant co-receptor,
Klotho, which are required for renal phosphate excretion.
Their deﬁciency causes hyperphosphatemia and heterotopic
mineralization,
22 which can be rescued by a low-phosphate
diet. In this translational model, vascular calciﬁcation
appears to be the mechanism by which high serum
phosphorus increases cardiovascular and mortality risk.
Low-phosphate diets improved survival along with prevent-
ing vascular calciﬁcation.
OUTCOME STUDIES OF PHOSPHORUS CORRECTION
Human studies demonstrating that reducing serum phos-
phorus concentrations decreases cardiovascular risk have not
been conducted. However, some studies have been conducted
that are supportive of the conclusion that phosphorus is a
cardiovascular risk factor. The Accelerated Mortality on Renal
Replacement study
23 (Figure 5) was a prospectively observed
cohort study of 10,044 incident hemodialysis patients,
comparing those who did with those who did not receive
any phosphate-binder treatment during the ﬁrst 90 days of
dialysis. Phosphate binder use was associated with signiﬁ-
cantly reduced mortality risk on multivariate analysis (on an
intent-to-treat or as-treated basis), as well as in a propensity
score-matched comparison. Beneﬁts were independent of
baseline serum phosphate levels, and thus may reﬂect lowered
levels of the phosphaturic factor ﬁbroblast growth factor-23,
which is induced up to 100-fold in untreated hyperphos-
phatemic dialysis patients.
The Renagel in New Dialysis study,
24 an 18-month
randomized, controlled trial of sevelamer HCl versus
calcium-containing phosphate binder in 109 new hemodia-
lysis patients, showed that among patients with baseline
coronary artery calciﬁcation, calcium binder use was asso-
ciated with more rapid and severe progression of calciﬁcation
than sevelamer HCl use. A pre-speciﬁed secondary end-point
analysis of the Renagel in New Dialysis study
25 revealed that,
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Figure 5|Effects of serum phosphate and phosphate binder use on survival in the Accelerated Mortality in Renal Replacement
study.
23 Survival of treated and untreated patients in the overall propensity score-matched cohort (a) and according to quartiles of baseline
serum phosphate (b–e). Reproduced by permission from Isakova et al.
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versus calcium-containing phosphate binders and followed
up for 44 months, baseline coronary artery calciﬁcation score
was a predictor of all-cause mortality. Sevelamer was
associated with a signiﬁcant survival beneﬁt versus calcium-
containing binders in this study.
CONCLUSIONS
From the discussion above, the following conclusions are
drawn. First, observational studies suggest that serum
phosphate is a cardiovascular risk factor in patients with
CKD and in the general population. Second, translational
studies demonstrate that hyperphosphatemia stimulates
atherosclerotic vascular calciﬁcation by inducing osteoblastic
gene expression in the aorta, and that correction of
hyperphosphatemia decreases vascular calciﬁcation. Third,
studies in vitro demonstrate that medium inorganic phos-
phate is an active signaling molecule, the receptor may be
Pit1, and phosphate directly stimulates osteoblastic tran-
scription factors. Fourth, human studies are consistent in
showing the effects of phosphate and its correction on
vascular calciﬁcation and cardiovascular mortality. However,
these studies are not formal outcome studies and are
insufﬁcient evidence without the translational data. Fifth,
the strong epidemiologic and mechanistic evidence suggest-
ing that serum phosphate is a cardiovascular risk factor needs
to be conﬁrmed by human prospective and outcome studies
to satisfy the rigorous deﬁnition of phosphorus as a
cardiovascular risk factor. Finally, in the meantime, before
formal outcome studies are completed, interventions to
maintain serum phosphate normal in patients with CKD
before end-stage renal disease are clearly warranted.
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